According to market observers, shares of the company are available at a premium of ₹101 in the grey market today ...

Anthem Biosciences’ IPO puts the spotlight on India’s contract drug manufacturing sector, as investor appetite swells and global firms diversify away from China.

Indian drugmaker Anthem Biosciences' ANTH.NS $395 million IPO was fully subscribed on the second day of bidding on Tuesday, ...

Anthem Biosciences' initial share sale received bids for 14,47,66,596 shares, as against 4,40,70,682 shares on offer, ...

The Rs 3,395 crore Initial Public Offering (IPO) of Anthem Biosciences, the Bangalore-based contract research, development, ...

The offering, the first IPO this year, attracted more than 32 billion dirhams ($3.5 bln) in demand for 500 million dirhams in shares. GSK seeks FDA nod for expanded use of RSV vaccine in adults ...

The managed office space and co-working industry in India has undergone significant transformation over the past decade, ...

Anthem Biosciences, ₹3,395 crore IPO was fully subscribed by Day 2, with strong interest from non-institutional investors, ...

The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity ...

With a unique business model rooted in innovation-led drug development services, the company is betting big on global ...

WeWork’s promoters, Embassy Buildcon and Ariel Way Tenant, are offloading a total of 4.37 crore equity shares in the IPO of ...

The Anthem Biosciences IPO, starting July 14, 2025, aims to raise ₹3,395 crore through an Offer for Sale of 5.96 crore shares by existing shareholders, without proceeds going to the company. Shares ...